ArticleCurrent infectious disease reports2014
Treatment of giardiasis: current status and future directions.
Article in Current infectious disease reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 68 citations in OpenAlex.
- Antiparasitic Activity ofVeterinary sciences · 2026Article
- Effects of Astragaloside IV Combined With Metronidazole on Cyst Shedding and Mucosal Immune and Inflammatory Responses in a Murine Model of Giardiasis.Journal of parasitology research · 2026Article
- From Treatment to Toxicity: Metronidazole-Induced Encephalopathy in a 79-Year-Old Woman.Clinical case reports · 2025Article
- Genotype-Specific Small EVs Released by Giardia lamblia Act as Mediators of Phenotypic Adaptation Under Metronidazole-Induced Stress.Journal of extracellular vesicles · 2025Article
- The therapeutic effects of vonoprazan against giardiasis in rats: parasitological, pathological, and immunological aspects.Parasitology research · 2025Article
- High efficacy of camphene and metronidazole combination therapy againstParasite epidemiology and control · 2025Article
- Potential activity ofFrontiers in pharmacology · 2025Article
- Insights into the Natural and Treatment Courses of Hepatitis B in Children: A Retrospective Study.Biomedicines · 2024Article
- Repurposing Terfenadine as a Novel Antigiardial Compound.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Analysis ofPharmaceuticals (Basel, Switzerland) · 2023Review
- Prevalence of Intestinal Parasitic Infections, Genotypes, and Drug Susceptibility ofTropical medicine and infectious disease · 2023Article
- Probiotics in the management of Giardia duodenalis: an update on potential mechanisms and outcomes.Naunyn-Schmiedeberg's archives of pharmacology · 2021Review
- Systematic review on medicinal plants used for the treatment ofSaudi journal of biological sciences · 2021Review
- Recent advances in functional research in Giardia intestinalis.Advances in parasitology · 2020Review
- Epidemiological distribution of genotypes of Giardia duodenalis in humans in Spain.Parasites & vectors · 2019Article
- Structure-based identification of a potential non-catalytic binding site for rational drug design in the fructose 1,6-biphosphate aldolase from Giardia lamblia.Scientific reports · 2019Article
- Article
- Disulfiram as a novel inactivator of Giardia lamblia triosephosphate isomerase with antigiardial potential.International journal for parasitology. Drugs and drug resistance · 2017Article
- Novel giardicidal compounds bearing proton pump inhibitor scaffold proceeding through triosephosphate isomerase inactivation.Scientific reports · 2017Article
- A novel in vitro image-based assay identifies new drug leads for giardiasis.International journal for parasitology. Drugs and drug resistance · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giardiasis is a common yet neglected cause of diarrheal illness worldwide. Antimicrobial therapy is usually but not always effective and drug resistance has become an increasing concern. Several promising drug candidates have been recently identified that can overcome antibiotic resistance in Giardia. These include derivatives of 5-nitroimidazoles and benzimidazoles, as well as hybrid compounds created from combinations of different antigiardial drugs. High-throughput screening of large compound libraries has been a productive strategy for identifying antigiardial activity in drugs already approved for other indications, e.g. auranofin. This article reviews the current treatment of giardiasis, mechanisms of resistance, advances in drug and vaccine development, and directions for further research on this significant human pathogen.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.